MENU
WGO
Back to Top
World Gastroenterology Organisation
World Gastroenterology Organisation
Follow
WGO: Facebook WGO: Twitter
Share

Constipation

Level: Meta-analyses, Systematic reviews, Practice guidelines: 47 Abstracts

Legend: : Key Development,  : Very Important,  : Important, [no star]: Special Mention

 

An update on anorectal disorders for gastroenterologists.
Bharucha AE(1), Rao SS(2)., Gastroenterology. 2014 Jan;146(1):37-45.e2. doi: 10.1053/j.gastro.2013.10.062.Epub 2013 Nov 6.

Comments: Important update on anorectal disorders.

  

American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome.
Weinberg DS, Smalley W, Heidelbaugh JJ, Sultan S; Amercian Gastroenterological Association., Gastroenterology. 2014 Nov;147(5):1146-8. doi: 10.1053/j.gastro.2014.09.001. Epub 2014 Sep 16. No abstract available. Erratum in: Gastroenterology. 2015 Feb;148(2):455. multiple investigator names added.
Comments: Management of IBS: guidelines

 

Biofeedback for treatment of chronic idiopathic constipation in adults.
Woodward S(1), Norton C, Chiarelli P., Cochrane Database Syst Rev. 2014 Mar 26;3:CD008486. doi:10.1002/14651858.CD008486.pub2.

Comments: Cochrane systematic review to conclude that there is currently insufficient evidence to allow firm conclusions regarding the efficacy and safety of biofeedback for chronic constipation.

 

Management of faecal incontinence and constipation in adults with centralneurological diseases.
Coggrave M(1), Norton C., Cochrane Database Syst Rev. 2013 Dec 18;12:CD002115. doi:10.1002/14651858.CD002115.pub4.

Comments: There is very limited evidence in favour of a bulk-forming laxative (psyllium), an isosmotic macrogol laxative, abdominal massage, electrical stimulation, an anticholinesterase-anticholinergic drug combination (neostigmine-glycopyrrolate), transanal irrigation, oral carbonated (rather than tap) water and abdominal massage. Confirmation is needed.

 

Efficacy of pharmacological therapies for the treatment of opioid-inducedconstipation: systematic review and meta-analysis.
Ford AC(1), Brenner DM, Schoenfeld PS., Am J Gastroenterol. 2013 Oct;108(10):1566-74; quiz 1575. doi:10.1038/ajg.2013.169. Epub 2013 Jun 11.

Comments: µ-Opioid receptor antagonists are effective in opioid-induced constipation. More data are required before the role of prucalopride or lubiprostone are clear.

 

American Gastroenterological Association medical position statement onconstipation.
American Gastroenterological Association, Bharucha AE, Dorn SD, Lembo A, Pressman A., Gastroenterology. 2013 Jan;144(1):211-7. doi: 10.1053/j.gastro.2012.10.029.

Comments: no abstract

 

Osmotic and stimulant laxatives for the management of childhood constipation.


Comments: This Cochrane review suggests that PEG preparations may be superior to placebo, lactulose and milk of magnesia for childhood constipation, but the overall quality of the studies was low. PEG appears safe and well tolerated. There is also evidence suggesting the efficacy of liquid paraffin (mineral oil) but not of lactulose although there is a lack of placebo controlled studies.

 

Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis.
Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Moayyedi P., Am J Gastroenterol. 2014 Oct;109(10):1547-61; quiz 1546, 1562. doi: 10.1038/ajg.2014.202. Epub 2014 Jul 29. Review.
Comments: About probiotics, prebiotics and synbiotics…

 

Management of faecal incontinence and constipation in adults with centralneurological diseases.
Coggrave M(1), Norton C, Cody JD., Cochrane Database Syst Rev. 2014 Jan 13;1:CD002115. doi:10.1002/14651858.CD002115.pub5.

Comments: Cochrane systematic review describing insufficient confirmative data on the management of faecal incontinence and constipation in adults with central neurological diseases.

 

Opioids for neuropathic pain.
McNicol ED(1), Midbari A, Eisenberg E., Cochrane Database Syst Rev. 2013 Aug 29;8:CD006146. doi:10.1002/14651858.CD006146.pub2.

Comments: Analgesic efficacy of opioids in chronic neuropathic pain is subject to considerable uncertainty.

 

Effects of linaclotide in patients with irritable bowel syndrome withconstipation or chronic constipation: a meta-analysis.
Videlock EJ(1), Cheng V, Cremonini F., Clin Gastroenterol Hepatol. 2013 Sep;11(9):1084-1092.e3; quiz e68. doi:10.1016/j.cgh.2013.04.032. Epub 2013 May 2.

Comments: Linaclotide, a minimally absorbed 14-amino acid peptide, improves bowel function and reduces abdominal pain in IBS with constipation.

 

Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in aphase 2 study.
Dove LS(1), Lembo A, Randall CW, Fogel R, Andrae D, Davenport JM, McIntyre G, Almenoff JS, Covington PS., Gastroenterology. 2013 Aug;145(2):329-38.e1. doi: 10.1053/j.gastro.2013.04.006.Epub 2013 Apr 9.

Comments: Phase 2 study of the mixed µ-opioid receptor agonist/d-opioid receptor antagonist eluxadoline in IBS with diarrhoea significantly improved abdominal pain and stool consistency.

 

Association between constipation and colorectal cancer: systematic review andmeta-analysis of observational studies.
Power AM, Talley NJ, Ford AC., Am J Gastroenterol. 2013 Jun;108(6):894-903; quiz 904. doi: 10.1038/ajg.2013.52. Epub 2013 Mar 12.

 

A 12-week, randomized, controlled trial with a 4-week randomized withdrawalperiod to evaluate the efficacy and safety of linaclotide in irritable bowelsyndrome with constipation.
Rao S, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, Shi K, MacDougall JE,Shao JZ, Eng P, Fox SM, Schneier HA, Kurtz CB, Johnston JM., Am J Gastroenterol. 2012 Nov;107(11):1714-24; quiz p.1725.

 

Linaclotide for irritable bowel syndrome with constipation: a 26-week,randomized, double-blind, placebo-controlled trial to evaluate efficacy andsafety.
Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, MacDougall JE, JiaXD, Shao JZ, Fitch DA, Baird MJ, Schneier HA, Johnston JM., Am J Gastroenterol. 2012 Nov;107(11):1702-12.

 

A prospective randomized trial of mosapride vs. placebo in constipation-predominant irritable bowel syndrome.
Mansour NM, Ghaith O, El-Halabi M, Sharara AI. Am J Gastroenterol. 2012 May;107(5):792-3. doi: 10.1038/ajg.2012.26.

Comments: Mosapride citrate, a selective partial 5?HT4 receptor agonist, which enhances gastrointestinal motility after accelerating the release of acetylcholine from nerves in the gastrointestinal tract was given to 21 patients with irritable bowel syndrome and constipation for 8-weeks but did not perform better than placebo.

 

Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome.
W Atkinson, S Lockhart, PJ Whorwell, B Keevil, LA Houghton, Gastroenterology. 2006 Jan:34-43

 

An open-label study of chronic polyethylene glycol laxative use in chronic constipation.
JA Di Palma, MV Cleveland, J McGowan, JL Herrera, Aliment Pharmacol Ther. 2007 Mar 15:703-8

 

Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia.
G Chiarioni, WE Whitehead, V Pezza, A Morelli, G Bassotti, Gastroenterology. 2006 Mar:657-64

 

Effect of tegaserod on recto-sigmoid tonic and phasic activity in constipation-predominant irritable bowel syndrome.
M Di Stefano, E Miceli, S Mazzocchi, P Tana, A Missanelli, GR Corazza, Am J Gastroenterol. 2007 Aug:1720-6

 

Efficacy and safety of traditional medical therapies for chronic constipation: systematic review.
D Ramkumar, SS Rao, Am J Gastroenterol. 2005 Apr:936-71

 

Review article: tegaserod -- the global experience.
WD Chey, Aliment Pharmacol Ther. 2004 Nov:15-9

 

Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome.
PP van der Veek, M van den Berg, YE de Kroon, HW Verspaget, AA Masclee, Am J Gastroenterol. 2005 Nov:2510-6

 

The role of glial cells and apoptosis of enteric neurones in the neuropathology of intractable slow transit constipation.
G Bassotti, V Villanacci, CA Maurer, S Fisogni, F Di Fabio, M Cadei, A Morelli, T Panagiotis, G Cathomas, B Salerni, Gut. 2006 Jan:41-6

 

Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: arandomized trial.
Horton MR, Santopietro V, Mathew L, Horton KM, Polito AJ, Liu MC, Danoff SK,Lechtzin N., Ann Intern Med. 2012 Sep 18;157(6):398-406. doi:10.7326/0003-4819-157-6-201209180-00003.

 

Prevalence of, and risk factors for, chronic idiopathic constipation in thecommunity: systematic review and meta-analysis.
Suares NC, Ford AC., Am J Gastroenterol. 2011 Sep;106(9):1582-91; quiz 1581, 1592. doi:10.1038/ajg.2011.164. Epub 2011 May 24.

 

Effect of laxatives and pharmacological therapies in chronic idiopathicconstipation: systematic review and meta-analysis.
Ford AC, Suares NC., Gut. 2011 Feb;60(2):209-18.

 

Meta-analysis: do irritable bowel syndrome symptoms vary between men and women?
Adeyemo MA, Spiegel BM, Chang L., Aliment Pharmacol Ther. 2010 Sep;32(6):738-55. doi:10.1111/j.1365-2036.2010.04409.x. Epub 2010 Jul 22.

  

Appropriateness of colonoscopy in Europe (EPAGE II). Functional bowel disorders: pain, constipation and bloating.
Schusselé Filliettaz S, Gonvers JJ, Peytremann-Bridevaux I, Arditi C, Delvaux M, Numans ME, Lorenzo-Zúñiga V, Dubois RW, Juillerat P, Burnand B, Pittet V, Vader JP, Froehlich F, EPAGE II Study Group, Endoscopy. 2009 Mar;41(3):234-9 Cat: Journal Article

 

Breath hydrogen test after a bean meal demonstrates delayed oro-cecal transit time in children with chronic constipation.
AC Soares, HM Lederman, U Fagundes-Neto, MB de Morais, J Pediatr Gastroenterol Nutr. 2005 Aug:221-4

 

Cecostomy in children with defecation disorders.
HM Mousa, MM van den Berg, DA Caniano, M Hogan, C Di Lorenzo, J Hayes, Dig Dis Sci. 2006 Jan:154-60

 

Change over time of bowel habit in irritable bowel syndrome: a prospective, observational, 1-year follow-up study (RITMO study).
V Garrigues, F Mearin, X Badía, A Balboa, J Benavent, A Caballero, E Domínguez, M Díaz-Rubio, M Roset, M Figueras, M Cucala, RITMO GROUP, Aliment Pharmacol Ther. 2007 Feb 1:323-32

 

Chronic constipation: a survey of the patient perspective.
JF Johanson, J Kralstein, Aliment Pharmacol Ther. 2007 Mar 1:599-608

 

Comorbidities associated with constipation in children referred for colon manometry may mask functional diagnoses.
JT Gertken, J Cocjin, N Pehlivanov, C Danda, PE Hyman, J Pediatr Gastroenterol Nutr. 2005 Sep:328-31

 

Decreased density of interstitial cells of Cajal and neuronal cells in patients with slow-transit constipation and acquired megacolon.
JI Lee, H Park, MA Kamm, IC Talbot, J Gastroenterol Hepatol. 2005 Aug:1292-8

 

Development of Functional Diarrhea, Constipation, Irritable Bowel Syndrome, and Dyspepsia During and After Traveling Outside the USA.
AK Tuteja, NJ Talley, SS Gelman, SC Adler, C Thompson, K Tolman, DC Hale, Dig Dis Sci. 2007 Jun 5

 

Epidemiology of childhood constipation: a systematic review.
MM van den Berg, MA Benninga, C Di Lorenzo, Am J Gastroenterol. 2006 Oct:2401-9

 

Etiologic factors of chronic constipation: review of the scientific evidence.
FW Leung, Dig Dis Sci. 2007 Feb:313-6

 

Functional bowel disorders.
GF Longstreth, WG Thompson, WD Chey, LA Houghton, F Mearin, RC Spiller, Gastroenterology. 2006 Apr:1480-91

 

In patients with slow transit constipation, the pattern of colonic transit delay does not differentiate between those with and without impaired rectal evacuation.
N Zarate, CH Knowles, M Newell, NW Garvie, MA Gladman, PJ Lunniss, SM Scott, Am J Gastroenterol. 2008 Feb:427-34

 

Outlet type constipation in Parkinson's disease: results of botulinum toxin treatment.
F Cadeddu, AR Bentivoglio, F Brandara, G Marniga, G Brisinda, G Maria, Aliment Pharmacol Ther. 2005 Nov 15:997-1003

 

Patients with irritable bowel syndrome or constipation have an increased risk for ischaemic colitis.
DC Suh, KH Kahler, IS Choi, H Shin, J Kralstein, M Shetzline, Aliment Pharmacol Ther. 2007 Mar 15:681-92

 

Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome.
J Tack, SJ Middleton, MC Horne, H Piessevaux, JS Bloor, NL Meyers, RM Palmer, Aliment Pharmacol Ther. 2006 Jun 1:1655-65

 

Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation.
KM Fock, A Wagner, Asia Pacific Gastroenterology Group, J Gastroenterol Hepatol. 2007 Aug:1190-8

 

Symptoms and pathophysiological correlations in patients with constipation and functional dyspepsia.
G Sarnelli, R Grasso, E Ierardi, F De Giorgi, MF Savarese, L Russo, G Budillon, R Cuomo, Digestion. 2005:225-30

 

Tegaserod: long-term treatment for irritable bowel syndrome patients with constipation in primary care.
P Layer, J Keller, S Mueller-Lissner, P Ruegg, H Loeffler, Digestion. 2005:238-44

 

Validation of the pediatric Rome II criteria for functional gastrointestinal disorders using the questionnaire on pediatric gastrointestinal symptoms.
A Caplan, L Walker, A Rasquin, J Pediatr Gastroenterol Nutr. 2005 Sep:305-16